搜尋
Neuronetics Inc
STIM添加自選
1.410USD
+0.060+4.44%
收盤 07/02, 13:00（美東）報價延遲15分鐘
98.11M總市值
虧損本益比TTM
關鍵數據
1.370今開
1.410最高
617.61K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.89%換手率
1.350昨收
1.335最低
604.24K成交額
虧損本益比靜
7.40市淨率
0.00%股息率 TTM
-27.84%ROA
4.84952週最高
0.61量比
-43.71M淨利潤
69.58M總股本
-0.5402每股盈餘TTM
1.07Beta
-152.36%ROE
0.80052週最低
5.56%振幅
46.89%毛利率
98.11M總市值
-0.47回報/風險
6.11%風險率
TradingKey Neuronetics Inc股票評分
單位: USD 更新時間: 2026-07-02操作建議
Neuronetics Inc當前公司基本面數據相對穩定，增長潛力較大。當前估值合理，在醫療設備與耗材行業排名103/204位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為4.33。中期看，股價處於下降通道。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Neuronetics Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Neuronetics Inc亮點
亮點風險
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
業績高增長
公司營業收入穩步增長，連續3年增長109.06%
利潤高增長
公司淨利潤處於行業前列，最新年度總收入149.16M美元
估值合理
公司最新PE估值-2.61，處於3年歷史合理位
機構減倉
最新機構持股47.87M股，環比減少13.05%
活躍度降低
近期活躍度降低，過去20天平均換手率-0.09
分析師目標
基於
3
分析師
買入
評級
4.333
目標均價
+218.63%
漲幅空間
Neuronetics Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Neuronetics Inc簡介
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
公司代碼STIM
公司Neuronetics Inc
CEOMr. Keith J. Sullivan
網址https://neurostar.com/neuronetics/
相關品種
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%熱門品種
52988.700
+146.200 (+0.28%)
29584.700
+273.300 (+0.93%)
7504.000
+32.500 (+0.43%)
15110.000
+307.000 (+2.07%)
69556.000
+1408.000 (+2.07%)
6379.400
+26.600 (+0.42%)
68.943
+0.599 (+0.88%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4180.090
+58.180 (+1.41%)
常見問題
Neuronetics Inc(STIM)的當前股價是多少？
Neuronetics Inc(STIM)的當前股價是 1.41。
Neuronetics Inc 的股票代碼是什麼？
Neuronetics Inc的股票代碼是STIM。
Neuronetics Inc股票的52週最高點是多少？
Neuronetics Inc股票的52週最高點是4.85。
Neuronetics Inc股票的52週最低點是多少？
Neuronetics Inc股票的52週最低點是0.80。
Neuronetics Inc的市值是多少？
Neuronetics Inc的市值是98.11M。
現在Neuronetics Inc(STIM)的股票是買入、持有還是賣出？
根據分析師評級，Neuronetics Inc(STIM)的總體評級為買入，目標價格為4.33。
Neuronetics Inc(STIM)股票的每股收益（EPS TTM）是多少
Neuronetics Inc(STIM)股票的每股收益（EPS TTM）是-0.59。